Stochastically curtailed phase II clinical trials

Statistics in Medicine

Volumn 26, Issue 7, 2007, Pages 1462-1472

  Ayalowo, A O ^a   Redden, D T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Conditional power; Efficacy; Phase II trials; Response proportion; Stochastic curtailment

Indexed keywords

ARTICLE; BINOMIAL DISTRIBUTION; CLINICAL RESEARCH; EFFECT SIZE; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; NULL HYPOTHESIS; POWER ANALYSIS; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE; SAMPLING ERROR; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE II; HUMANS; RESEARCH DESIGN; SAMPLE SIZE; STOCHASTIC PROCESSES;

EID: 33947165725     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2653     Document Type: Article

References (21)

1. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 1961; 13:346-353.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
3. Kramar A, Potvin D, Hill C. Multistage designs for phase II clinical trials: statistical issues in cancer research. British Journal of Cancer 1996; 74:1317-1320.
4. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC Press: Boca Raton, 2000; 205-215.
5. Lan KK, Whites J. The B-value: a tool for monitoring data. Biometrics 1988; 44:579-585.
6. Leung DH, Wang Y, Amar D. Early stopping by using stochastic curtailment in a three-arm sequential trial. Applied Statistics 2003; 52:139-152.
7. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979; 35:775-783.
8. Choi SC, Smith PJ, Becker DP. Early decision in clinical trials when treatment differences are small: Experience of a controlled trial in head trauma. Controlled Clinical Trials 1985; 6:280-288.
9. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 1986; 7:8-17.
10. Sylvester R. A Bayesian approach to the design of phase II clinical trials. Biometrics 1988; 44:823-836.
11. Thall P, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994; 50:337-349.
12. Jung SH, Lee T, Kim K, George S. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 2004; 23:561-569.
13. Jennison C. Bootstrap tests and confidence intervals for a hazard ratio when the number of observed failures is small, with applications to group sequential survival studies. Computing Sciences and Statistics, vol. 23. Springer: New York, 1990; 89-97.
14. Xiong X. A class of sequential conditional probability ratio tests. Journal of the American Statistical Association 1995; 90:1463-1473.
15. Tan M, Xiong X. Continuous and group sequential conditional probability ratio tests for phase II clinical trials. Statistics in Medicine 1996; 15:2037-2051.
16. Tan M, Xiong X, Kutner MH. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Biometrics 1998; 54:682-695.
17. Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Sequential Analysis 1982; 1:207-209.
18. Jennison C, Turnbill BW. Statistical approaches to interim monitoring of medical trials: a review and commentary. Statistical Science 1990; 5:299-317.
19. Pepe MS, Anderson GL. Two-stage experimental designs: early stopping with a negative result. Applied Statistics 1992; 41:181-190.
20. 0 embedded in sequential tests. Statistics in Medicine 1997; 16:465-477.
21. 0 based on conditional power: approximations and comparisons. Biometrics 1997; 53:794-806.